On April 15, 2021, NanoView Biosciences, Inc. ("NanoView"), a leading biomarker characterization company in the emerging field of extracellular vesicle (EV) biology, today announced a collaboration agreement with Beth Israel Deaconess Medical Center ("BIDMC") to study the involvement of biomarkers carried by exosomes in patients undergoing immune checkpoint inhibitor therapy ("ICIT") for cancer. The “ExoPD-L1 to Predict Immunotherapy Response in Cancer (‘EPIC’) Study” will specifically investigate Programmed Death-Ligand 1 ("PD-L1") and status of disease, as well as response to therapy. Exosomes are small EVs, 50-150 nm in size, that facilitate communication between cells by shuttling proteins, lipids, and nucleic acids. NanoView's platform technology, ExoView®, will be used in the EPIC Study to characterize PD-L1 and other biomarkers carried by exosomes in plasma samples from patients undergoing ICIT. "NanoView is excited to collaborate with BIDMC through the EPIC Study," stated Jerry Williamson, CEO of NanoView. "We are pleased that BIDMC will help evaluate data from our ExoView platform to better understand the role that exosome-associated biomarkers play in disease status and therapeutic response for cancer patients." Bruno Bockorny, MD, an oncologist from BIDMC, will serve as the Study Principal Investigator. Co-investigators from the Division of Medical Oncology and Immunotherapy Institute at BIDMC will also participate. "Disease status and response to therapy are difficult to predict for patients involved in ICIT and our aim is to continue to look for better clues that will deliver better outcomes," stated Dr. Bockorny.
Login Or Register To Read Full Story